
|Videos|April 27, 2017
Advancing Innovative Technology into Safe and Effective Medicines
Advertisement
Episodes in this series

Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes surrounding an activator of an enzyme called glucokinase and a glucagon-like receptor agonist. “GLP-1s right now are all injectables, and they all have side effects of nausea and vomiting. In our particular case, ours is an oral molecule, and it also doesn’t seem to have the gastrointestinal side effects.”
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
2
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
3
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
4
What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD
5





















































































